Inkef Capital

Inkef Capital is an Amsterdam-based venture capital firm that backs early-stage technology and healthcare companies in Europe. Founded in 2010, it positions itself as a patient, long-term investor capable of supporting portfolio companies through multiple funding rounds, with a focus on technology, healthcare and biotech sectors and growth toward international markets.

Carien Beyer

Senior Associate

Estelle Botbol

Associate

Simone Botti

Partner

Roel Bulthuis

Managing Director

Ivan Burkov

Senior Associate

Marcos Casado Murillo

Associate

Jacobo Cucalon

Associate

Reitze Douma

Managing Partner

Robert Jan Galema

Managing Director

Corné Jansen

Partner

Cher Shen Kiar

Associate

Frank Lansink

Senior Partner

Carien Nantois-Beijer

Principal

Kunal Singhania

Associate

Michael Stam

Investor

Amanda Stenbaek

Associate

Tim Strüven

Associate

Thijs Cohen Tervaert

Partner

Alice Vickers

Associate

Laura Waldenstrom

Senior Associate

Kyang Yung

Partner

Past deals in Benelux

Onward

Post in 2024
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Silverflow

Series A in 2023
Founded in 2019, Silverflow is a Dutch company specializing in cloud-based payment processing technology. It offers direct access to card networks for payment service providers (PSPs), enabling them to accelerate innovation, gain real-time insights into transaction fees, and acquire smart data directly from the networks.

Precirix

Series B in 2022
Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

ViCentra

Series C in 2021
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Silverflow

Series A in 2021
Founded in 2019, Silverflow is a Dutch company specializing in cloud-based payment processing technology. It offers direct access to card networks for payment service providers (PSPs), enabling them to accelerate innovation, gain real-time insights into transaction fees, and acquire smart data directly from the networks.

Urban Sports Club

Venture Round in 2021
Urban Sports Club operates a membership-based platform that provides access to fitness studios, classes, and health activities through an extensive network of partner facilities across Europe. The service offers a flexible sports flat-rate with access to more than 50 activity types and over 10,000 partner venues in multiple European countries, supporting both individual and corporate users to pursue varied workouts, team sports, wellness, and related activities under one membership.

Onward

Venture Round in 2021
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Silverflow

Seed Round in 2020
Founded in 2019, Silverflow is a Dutch company specializing in cloud-based payment processing technology. It offers direct access to card networks for payment service providers (PSPs), enabling them to accelerate innovation, gain real-time insights into transaction fees, and acquire smart data directly from the networks.

Salvia BioElectronics

Series A in 2020
Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

ViCentra

Venture Round in 2020
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Cashforce

Series A in 2019
Cashforce BV, established in 2013, is a Belgian company with offices in Antwerp, New York, Amsterdam, Copenhagen, and London. It specializes in a smart cash flow management and forecasting platform, enabling users to predict cash inflows and outflows across multiple companies, bank accounts, and currencies. The platform integrates seamlessly with various ERPs and banking systems, providing detailed transaction-level insights and AI-based cash flow scenario simulations. Cashforce serves multinational corporations across diverse industries in over 120 countries, empowering CFOs, finance teams, and treasury departments to enhance cash visibility, optimize working capital, and make data-driven decisions.

Urban Sports Club

Venture Round in 2019
Urban Sports Club operates a membership-based platform that provides access to fitness studios, classes, and health activities through an extensive network of partner facilities across Europe. The service offers a flexible sports flat-rate with access to more than 50 activity types and over 10,000 partner venues in multiple European countries, supporting both individual and corporate users to pursue varied workouts, team sports, wellness, and related activities under one membership.

Blendle

Series A in 2017
Blendle is a digital media platform that allows readers to purchase articles from various Dutch and Belgian newspapers and magazines, including prominent publications like the Economist. Users can buy individual articles for prices ranging from €0.10 to €0.30, and they are presented with a selection of recommendations similar to social media feeds. New users are provided with an initial credit of €2.50 to explore the platform. The service includes a brief refund window for article purchases, after which Blendle retains a 30% commission on sales. By offering a pay-per-article model, Blendle aims to enhance access to quality journalism and cater to readers' preferences through personalized recommendations.

Bloomon

Series B in 2017
Founded in 2014, Bloomon is a Dutch company that specializes in online retail of flowers. It focuses on delivering high-quality products directly to consumers across Europe through its subscription-based platform.

Onward

Series A in 2016
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

ViCentra

Series B in 2016
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

InteRNA Technologies

Series A in 2015
InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.

Audion Therapeutics

Grant in 2015
Audion Therapeutics BV is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for ear-related diseases, particularly hearing loss. Established in 2008 and headquartered in Amsterdam, the Netherlands, the company concentrates on small molecule drug discovery aimed at regenerating inner hair cells, which are crucial for hearing. Audion Therapeutics is developing therapies that target the gamma-secretase protein complex to restore auditory function, addressing sensorineural hearing loss often associated with aging. The company's intellectual property portfolio encompasses novel molecules, advanced delivery systems, and drug discovery tools specifically designed for hearing loss research.

Bloomon

Series A in 2015
Founded in 2014, Bloomon is a Dutch company that specializes in online retail of flowers. It focuses on delivering high-quality products directly to consumers across Europe through its subscription-based platform.

ViCentra

Series A in 2013
ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Sapiens Steering Brain Stimulation

Series A in 2013
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.

Lanthio Pharma

Series A in 2012
Lanthio Pharma B.V. is a biopharmaceutical company based in Groningen, the Netherlands, focused on the discovery and development of novel lantipeptide drugs targeting serious medical conditions such as fibrosis, stroke, heart failure, and multiple sclerosis. Founded in 2010, the company leverages its proprietary LanthioPep technology to create peptide therapeutics that exhibit enhanced resistance to degradation, high specificity for receptors, and improved intrinsic activity. Among its key products are LP2, a selective angiotensin II type 2 receptor agonist aimed at treating fibrosis; PanCyte, designed for ischemic stroke recovery and peripheral vascular disease; and a lanthi-apelin agonist targeting the APJ receptor, which plays a role in various organ systems. Lanthio Pharma is committed to advancing therapeutic options for patients suffering from these severe diseases.

Robin Radar Systems

Series A in 2011
Robin Radar Systems B.V. is a company based in The Hague, Netherlands, specializing in advanced bird detection systems that monitor bird movements to enhance safety and operational efficiency. The company offers several radar systems, including the 2D Mobile system, which detects the presence, location, direction, speed, and route of birds up to 20 kilometers away; the 3D Fixed system, which provides similar data for heights up to 10 kilometers; and the 3D Flex system that combines horizontal S-band radar with flexible frequency modulation. Additionally, Robin Radar Systems offers the Military XL, designed to assist air forces in preventing bird strikes. Established in 2010 as a spin-off from the Dutch Research Institute for Applied Science, the company has exclusive access to advanced bird radar technology developed since the 1970s. Robin Radar Systems is committed to delivering high-quality technology and comprehensive support services, ensuring their solutions effectively meet client needs in various sectors such as aviation, wind energy, and environmental research.

Salvia BioElectronics

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.